» Articles » PMID: 35888591

Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study

Overview
Publisher MDPI
Specialty General Medicine
Date 2022 Jul 27
PMID 35888591
Authors
Affiliations
Soon will be listed here.
Abstract

Background and Objectives: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of the present study was to assess the impact of DM on metastatic CRC (mCRC), and to identify possible predictive factors in the successful treatment of mCRC. Materials and Methods: 468 patients with mCRC were included in this retrospective, observational study. A total of 8669 oncological treatment cycles related to 988 distinct chemotherapy lines were analyzed. Data regarding lines of treatment and blood panel values were obtained from the Oncohelp Hospital database. Results: The presence of DM in male patients >70 years was a negative predictor (RR = 1.66 and a p = 0.05). DM seemed to have a detrimental effect in patients whose treatment included bevacizumab (median time to treatment failure -TTF- 94 days for DM+ cases compared to 114 days for DM-patients, p = 0.07). Analysis of treatments including bevacizumab based on DM status revealed lower values of mean TTF in DM+ female patients versus DM-(81.08 days versus 193.09 days, p < 0.001). It was also observed that DM+ patients had a higher mean TTF when undergoing anti-EGFR (epidermal growth factor) therapy (median TTF 143 days for DM+ patients versus 97.5 days for those without DM, p = 0.06). Conclusions: The favorable predictive factors identified were the inclusion of antiangiogenic agents, a higher hemoglobin value, a higher lymphocyte count, the inclusion of anti-EGFR treatment for DM+ patients, a higher creatinine, and a higher lymphocyte count in treatment lines that included anti-EGFR treatment. Unfavorable predictive factors were represented by the presence of DM in female patients undergoing antiangiogenic treatment, neutropenia in male patients, the association of oxaliplatin and antiangiogenic agents, and a higher monocyte count in the aforementioned treatment lines.

Citing Articles

Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

Braha A, Timar B, Ivan V, Balica M, Daniluc L, Timar R J Clin Med. 2024; 13(19).

PMID: 39407960 PMC: 11477181. DOI: 10.3390/jcm13195901.


Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial.

Perva I, Simina I, Bende R, Motofelea A, Chirita Emandi A, Andreescu N Medicina (Kaunas). 2024; 60(8).

PMID: 39202647 PMC: 11356300. DOI: 10.3390/medicina60081366.

References
1.
Balasubramanyam M . Diabetic oncopathy--one more yet another deadly diabetic complication!. Indian J Med Res. 2014; 140(1):15-8. PMC: 4181152. View

2.
Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X . Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020; 10(1):14790. PMC: 7478957. DOI: 10.1038/s41598-020-71908-9. View

3.
Wong M, Huang J, Lok V, Wang J, Fung F, Ding H . Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location. Clin Gastroenterol Hepatol. 2020; 19(5):955-966.e61. DOI: 10.1016/j.cgh.2020.02.026. View

4.
Arnold M, Sierra M, Laversanne M, Soerjomataram I, Jemal A, Bray F . Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016; 66(4):683-691. DOI: 10.1136/gutjnl-2015-310912. View

5.
Li J, Ma X, Chakravarti D, Shalapour S, DePinho R . Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021; 35(11-12):787-820. PMC: 8168558. DOI: 10.1101/gad.348226.120. View